Gilead Sciences, Inc. (NASDAQ:GILD) hasn’t been able to bring a smile on the investors’ faces throughout the first three quarters of 2016, and in the last quarter as well, the company did not break the ice. Following the downward trend, the company announced its Q4 2016 results recently, and reported $3.1 billion Net income from continuing operations and $2.70 adjusted EPS. For the same duration in 2015, these figures were $4.7 billion and $3.32, respectively; marking a decline of 34% in Net income and 18.7% in EPS on YoY basis.
Everything’s down for Gilead Sciences in Q4 2016
The net income of company has fallen in Q4 2016, sales have fallen and Adjusted EPS too, have dropped. The company’s Q4 2016 sales were $7.3 billion, in comparison to $8.5 billion in Q4 2015, a drop by 14.1% on year over year basis.
The worse part for the shareholders is that the future looks bleak as well. The road ahead isn’t merry because of the rising costs of Gilead’s research and development activities in the fourth quarter of 2016. The cost of R&D for company has soared by almost 60% on YoY basis to $1.2 billion.
Gilead looks for advancing product pipeline; but the financial figures are dropping
The company, of late, has been spending exuberant amounts on product pipeline advancement. At present, it has as many as 28 important clinical studies going on. Among these, ten studies are almost in their final stages with larger scope. The late-stage trials of these studies are compelling the company for expensive R&D.
Meanwhile, the full-year revenue for 2016 is $30.4 billion (down 6.9%) and the full year earnings stood at $13.5 billion (down 25.4%). The company’s cash, at the end of year was $32.4 billion (including cash, marketable securities and cash equivalents).
The only reprise for the shareholders and company can be $16.7 billion in operating cash flow for 2016. Out of this, $11 billion has been used for buying stock, while $2.5 billion is used for paying dividend.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.